KZR-616 demonstrates clinically meaningful benefit in patients with lupus nephritis, with 4 out of 5 patients achieving either a partial or complete renal response at end of treatment
KZR-616 maintained a favorable safety and tolerability profile over the six-month treatment period
Company-hosted investor and analyst conference call and webcast with guest investigator to be held today at 4:30pm ET
Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today reported interim results from the Phase 2 portion of its MISSION clinical trial evaluating KZR-616, a first-in-class selective immunoproteasome inhibitor, in patients with active, proliferative lupus nephritis (LN).
"The MISSION Phase 2 interim results present a strong signal that KZR-616 is active and could be a meaningful therapy for patients with lupus nephritis, a long term and difficult to treat disease," said Noreen R. Henig, M.D., Kezar’s Chief Medical Officer. "Reduction in proteinuria, as quickly as possible, is an important therapeutic goal for patients with lupus nephritis, and we observed meaningful reductions at 6 months as well as encouraging data at 3 months. KZR-616 continues to appear to be immunomodulatory rather than immunosuppressive, which we believe could offer advantages over current treatments available. Based on these interim findings, we look forward to reporting top-line data in the second quarter of 2022."
https://finance.yahoo.com/news/kezar-life-sciences-announces-interim-210500176.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.